SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
507 31 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
457ASCO-GU meetinglibrary.asco.org <22 pts had available baseline PD-L1 resultsMiljenko Zuanic-2/11/2019
456Than again, he is/was strong seller from 2014! finviz.comMiljenko Zuanic-1/30/2019
455Nicholson J. sold without any *reserve* for taxes. Well, he can sell from main hMiljenko Zuanic-1/30/2019
454Oppenheimer join club with 10% stake: secfilings.nasdaq.comMiljenko Zuanic-1/19/2019
453Neoleukin...... endpts.comscaram(o)uche-1/11/2019
452Given that pointer came from Andy Biotech, imagine most have seen this..... natscaram(o)uche-1/10/2019
451Nektar jumps nearly 10% after laying out anticipated milestones for 2019 theflyJulius Wong-1/8/2019
450RE; NKTR-214, JPM update....NSCLC Pivot2 cohorts update at ESMO-19. Oh my God,..Miljenko Zuanic-1/8/2019
449Yes! (PIVOT-10)Miljenko Zuanic-1/2/2019
448This is *the* Opdivo/NKTR-214 pivotal in UC?DewDiligence_on_SI-1/2/2019
447Investor expected P3 mUC with low PD-1 expression, however P2 was seen as step dMiljenko Zuanic-1/2/2019
446It certainly has a chance. BMY would not proceed with phase-3 trials in multipleDewDiligence_on_SI-11/11/2018
445After revisiting SITC presentation, nektar.com and clearing my mind/hart....I cMiljenko Zuanic-11/11/2018
444Hard to say what will come out of SITC/ASH (read-out of 3Q cc), most likely CR-%Miljenko Zuanic-11/8/2018
443So, IF NKTR-214 does not work, how can ALKS 4230? seekingalpha.com Doses are evMiljenko Zuanic-11/6/2018
442To comment further (maybe it will make me fill better), it is BMY who rushed troMiljenko Zuanic-11/6/2018
441Thanks. IF you eliminate super-progressed (one or two from first 28, and 2 fromMiljenko Zuanic-11/6/2018
440SITC melanoma data for IL-2/PD-1 program looks a bit weak. That's probably ttuck-11/6/2018
439I guess Street do not like collaboration outside BMY targets/indications? financMiljenko Zuanic-11/6/2018
438Continuation on the same topic. Vantage stories are most of the time well balancMiljenko Zuanic-10/24/2018
437From other tread: Message 31849702 <"Per MofA, it does not looks that ROMiljenko Zuanic-10/23/2018
436Mars is unusually close to Earth right now, so the timing is fortuitous!DewDiligence_on_SI-10/16/2018
435BMY/NKTR are "very serious" about P3-melanoma trials. Very soon they wMiljenko Zuanic-10/16/2018
434But, also it is not from that pure nurse. Someone put some efforts in addressingMiljenko Zuanic-10/4/2018
433<Though its certainly lacking management has given an explanation (the data nMiljenko Zuanic-10/4/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News